Brentuximab vedotin in the treatment of relapsed and refractory forms of Hodgkin lymphoma | Zendy

AI Assistant Blog Pricing

Open Access

Brentuximab vedotin in the treatment of relapsed and refractory forms of Hodgkin lymphoma

Author(s) -

Demina Ea

Publication year - 2016

Publication title -

journal of modern oncology

Language(s) - English

Resource type - Journals

eISSN - 1815-1442

pISSN - 1815-1434

DOI - 10.26442/1815-1434_2016.2.15-18

Subject(s) - brentuximab vedotin , refractory (planetary science) , hodgkin lymphoma , oncology , medicine , lymphoma , cancer research , materials science , metallurgy

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom

About

About Careers Publisher Partners Contact Us Our institutional solutions Get Organisational Trial or Quote

Learn

FAQs Blog Terms of Use Privacy Policy

Download the Zendy App

Download on the

Discover

Explore

Copyright Knowledge E © 2026. All Rights Reserved.